Endothelial progenitor cells homing to the orthotopic implanted liver tumor of nude mice

Abstract

This study investigated the “homing” phenomenon in hepatocellular carcinoma (HCC). The “homing” specificity of endothelial progenitor cells (EPC) by establishing an orthotopic implantation model in nude mice. EPCs harvested from the marrow cells were separated by density gradient centrifugation. Fluorescence microscope, flow cytometry (FCM) and double fluorescence staining with FITC-UEA-I and DiI-ac-LDL, were employed to identify the cells. 4′,6-diamidino-2-phenylindole (DAPI) labelling and real-time PCR were used for detecting the expression of CD133 and chemokines to trace and observe the distribution of EPCs. Our results showed that the distribution rate of EPCs was obviously higher than that in other important organs and the negative control group. Detection of CD133 and chemokines yielded similar results in difference tissues. Our experiment confirmed that the chemotaxis of EPCs does exist in HCC. Moreover, HIF-1α, SDF-1 and VEGF might play important roles in the “homing” of EPCs in HCC. EPCs might be a potential candidate for targeting vector of HCC for gene therapy.

Keywords

EPCs / hepatocellular carcinoma / homing / targeted therapy / gene therapy

References

[1] UrbichC., DimmelerS.. Endothelial progenitor cells: characterization and role in vascular biology. Circ Res, 2004, 95(4): 343-353

[2] KhakooA.Y., FinkelT.. Endothelial progenitor cells. Annu Rev Med, 2005, 56: 79-101

[3] AsaharaT., MuroharaT., SullivanA., et al.. Isolation of putative progenitor endothelial cells for angiogenesis. Science, 1997, 275(5302): 964-967

[4] HristovM., ErlW., WeberP.C.. Endothelial progenitor cells: mobilization, differentiation, and homing. Arterioscler Thromb Vasc Biol, 2003, 23(7): 1185-1189

[5] SchattemanG.C.. Adult bone marrow-derived hemangioblasts endothelial cell progenitors and EPCs. Curr Top Dev Biol, 2004, 64: 141-180

[6] YuD., SunX., QiuY., et al.. Identification and clinical significance of mobilized endothelial progenitor cells in tumor vasculogenesis of hepatocellular carcinomar. Clin Cancer Res, 2007, 13(3): 3814-3824

[7] GimbroneM.A.Jr, LeapmanS.B., CotranR.S., et al.. Tumor dormancy in vivo by prevention of neovascularization. Exp Med, 1972, 136(2): 261-276

[8] RisauW., FlammeI.. Vasculogenesis. Ann Rev Cell Dev Biology, 1995, 11: 73-91

[9] FolkmanJ., ShingY.. Angiogenesis. J Biol Chem, 1992, 267(16): 10931-10934

[10] FolkmanJ.. Clinical applications of research on angiogenesis. N Engl J Med, 1995, 333(26): 1757-1763

[11] ReyesM., DudekA., JahagirdarB., et al.. Origin of endothelial progenitors in human postnatal bone marrow. Clin Invest, 2002, 109(3): 337-346

[12] AnnabiB., NaudE., LeeY.T., et al.. Vascular progenitors derived from murine bone marrow stromal cells are regulated by fibroblast growth factor and are avidly recruited by vascularizing tumors. Cell Biochem, 2004, 91(6): 1146-1158

[13] LydenD., HattoriK., DiasS., et al.. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med, 2001, 7(11): 1194-1201

[14] LarrivéeB., NiessenK., PolletI., et al.. Contribution of marrow-derived endothelial precursors to tumor vasculature. J Immunol, 2005, 175(5): 2890-2899

[15] MooreX.L., LuJ., SunL., et al.. Endotheliar progenitor cells’ “homing” specificity to brain tumors. Gene Ther, 2004, 11(10): 811-818

[16] GothertJ.R., GustinS.E., van EekelenJ.A., et al.. Genetically tagging endothelial cells in vivo: bone marrow-derived cells do not contribute to tumor endothelium. Blood, 2004, 104(6): 1769-1777

[17] WeisslederR.. Bone marrow-derived lin(−)c-kit(+)sca-1+ stem cells do not contribute to vasculogenesis in Lewis lung carcinoma. Neoplasia, 2005, 7(3): 234-240

[18] CarrB.I.. Hepatocellular carcinoma: current management and future trends. Gastroenterology, 2004, 127(5Suppl1): S218-S224

[19] RibattiD., VaccaA., NicoB., et al.. Postnatal vasculogenesis. Mech Devt, 2001, 100(2): 157-163

[20] DaweR.S.. Hepatocelluar carcinoma. Lancet, 2004, 363(9412): 899

[21] JanicB., ArbabA.S.. The role and therapeutic potential of endothelial progenitor cells in tumor neovascularization. ScientificWorldJournal, 2010, 10: 1088-1099

[22] YoungP.P., VaughanD.E., HatzopoulosA.K., et al.. Biological properties of endothelial progenitor cells (EPCs) and their potential for cell therapy. Prog Cardiovasc Dis, 2007, 49(6): 421-429

[23] SuuronenE.J., WongS., KapilaV., et al.. Generation of CD133+ cell from CD133-peripheral blood mononuclear cells and their properties. Cardiovasc Res, 2006, 70(1): 126-135

[24] UrsulaM., ErgünS., SchumacherU., et al.. In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood, 2000, 95(10): 3106-3112

[25] DzauV., GnecchiM., PachoriA.S., et al.. Therapeutic potential of endothelial progenitor cells in cardiovascular diseases. Hypertension, 2005, 46(1): 7-14

[26] RumpoldH., WolfD., KoeckR., et al.. Endothelial progenitor cells: a source for therapeutic vasculogenesis?. Cell Mol Med, 2004, 8(40): 509-516

[27] ShakedY., CiarrocchiA., FrancoM., et al.. Therapy induced acute recruitment of circulating endothelial progenitor cells to tumors. Science, 2006, 313(5794): 1785-1794